← SynDRA
XL-228
SynDRA canonical compound SYN0038220 — structure-anchored drug synonym record
Clinical phase
Phase 1
Primary target(s)
AURKA | FGF2 | IGF1R | SRC
Mechanism of action
Abl kinase inhibitor | insulin growth factor receptor inhibitor | SRC inhibitor
All known targets
IGF1R
SRC
ABL1
AURKA
BLK
FGF2
FGR
FRK
FYN
HCK
LCK
LYN
Mechanisms of action (all sources)
ABL1 INHIBITOR
Tyrosine-protein kinase ABL inhibitor
IGF1R INHIBITOR
Insulin-like growth factor I receptor inhibitor
FYN INHIBITOR
SRC inhibitor
LCK INHIBITOR
YES1 INHIBITOR
BLK INHIBITOR
HCK INHIBITOR
LYN INHIBITOR
FRK INHIBITOR
Cross-references
PubChem CID:
59757974
ChEMBL:
CHEMBL3545085
DrugBank:
DB05184
TTD: D03ZXZ
Synonyms
Exel-2280
XL228
XL 228
UNII-33M2XSK003
33M2XSK003
4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine
SCHEMBL11342904
CHEMBL3545085
AOB5553
EX-A1596
BCP08143
ZINC203005669
AKOS030526975
CS-1648
NCGC00378978-05
SC-95574
AS-16897
HY-15749
AC-30228
2,4-Pyrimidinediamine, N(sup 4)-(5-cyclopropyl-1H-pyrazol-3-yl)-N(sup 2)-((3-(1-methylethyl)-5-isoxazolyl)methyl)-6-(4-methyl-1-piperazinyl)-
KB-303240
RefChem:902364
Tyrosine Kinase Inhibitor XL228
C22H31N9O
MFCD26793867
orb1307597
SCHEMBL29356150
GLXC-06661
YKB28007
NSC778366
NSC800970
s1272
NSC-778366
NSC-800970
XL-228?
NCGC00378978-03
DA-59189
X4400
F84974
Look up XL-228 in the interactive SynDRA portal →